GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Penumbra Inc (NYSE:PEN) » Definitions » Equity-to-Asset

Penumbra (Penumbra) Equity-to-Asset : 0.76 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Penumbra Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Penumbra's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,179 Mil. Penumbra's Total Assets for the quarter that ended in Dec. 2023 was $1,556 Mil. Therefore, Penumbra's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.76.

The historical rank and industry rank for Penumbra's Equity-to-Asset or its related term are showing as below:

PEN' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.1   Med: 0.77   Max: 0.88
Current: 0.76

During the past 12 years, the highest Equity to Asset Ratio of Penumbra was 0.88. The lowest was -0.10. And the median was 0.77.

PEN's Equity-to-Asset is ranked better than
68.28% of 870 companies
in the Medical Devices & Instruments industry
Industry Median: 0.65 vs PEN: 0.76

Penumbra Equity-to-Asset Historical Data

The historical data trend for Penumbra's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Penumbra Equity-to-Asset Chart

Penumbra Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 0.78 0.77 0.73 0.76

Penumbra Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.73 0.73 0.75 0.75 0.76

Competitive Comparison of Penumbra's Equity-to-Asset

For the Medical Devices subindustry, Penumbra's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Penumbra's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Penumbra's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Penumbra's Equity-to-Asset falls into.



Penumbra Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Penumbra's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1178.944/1556.305
=0.76

Penumbra's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1178.944/1556.305
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Penumbra  (NYSE:PEN) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Penumbra Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Penumbra's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Penumbra (Penumbra) Business Description

Traded in Other Exchanges
Address
One Penumbra Place, Alameda, CA, USA, 94502
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
Executives
Harpreet Grewal director C/O VISTAPRINT USA, INCORPORATED, 100 HAYDEN AVE., LEXINGTON MA 02050
Surbhi Sarna director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Johanna Roberts officer: EVP, Gen. Counsel & Secretary PENUMBRA, INC., ONE PENUMBRA PLACE, ALAMEDA CA 94502
Bridget O'rourke director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Adam Elsesser director, officer: Chairman, CEO and President 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Don W. Kassing director 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Thomas Wilder director 2 MUSICK, IRVINE CA 92618
Arani Bose director, officer: Chief Innovator 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Lynn Rothman officer: EVP and Chief Business Officer 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
James Robert Pray officer: President, International 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sridhar Kosaraju officer: CFO and Head of Strategy 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Maggie Yuen officer: Chief Financial Officer ONE PENUMBRA PLACE, ALAMEDA CA 94502
Lambert Shiu officer: Chief Accounting Officer ONE PENUMBRA PLACE, ALAMEDA CA 94502
Janet Leeds director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Robert D. Evans officer: EVP, Gen. Counsel & Secretary ONE PENUMBRA PLACE, 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502